Pfizer’s respiratory syncytial virus vaccine was more than 90% effective among older adults during the first season it was ...

Video above: FDA votes to authorize more COVID-19 boosters, mix-and-matching doses in some casesA booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy — 95.6% — ...

Pfizer Inc said on Monday its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study, a major victory in the fight against the pandemic.

With flu season underway and new, developing COVID-19 strains, health professionals continue to stress the importance of receiving an updated vaccine. On Oct. 23, the Centers for Disease Control and ...

Please provide your email address to receive an email when new articles are posted on . RSVpreF showed effectiveness of 90% or higher regardless of the study controls used. The results fill data gaps ...

SAN FRANCISCO -- Another COVID-19 vaccine -- AstraZeneca -- is poised to arrive in the U.S., bringing a fourth option for Americans. Each vaccine is administered slightly differently, some can result ...

Over the course of a two-day meeting, vaccine advisers to the US Food and Drug Administration voted in favor of approval for RSV vaccines for adults over the age of 60. The vaccine candidates, made by ...

Pfizer Inc said on Wednesday that final results from the late-stage trial of its COVID-19 vaccine showed it was 95% effective ...

The United States is poised to get a third coronavirus vaccine -- this one made by Johnson & Johnson. The US Food and Drug Administration has given the vaccine emergency use authorization, the Centers ...

The study will examine vaccine safety, efficacy and immunity at lower doses. Pfizer is advancing Phase 2/3 clinical trials for young kids at lower doses than vaccines for adults, the pharmaceutical ...